"One Smart AI Pen", currently launched for crowdfunding on Kickstarter. | Credit: Zakwan Ahmad on Kickstarter On March 1st, engineer Zakwan Ahmad launched his concept for "The One Smart AI Pen" on ...

Perplexity AI is an AI-driven search engine and chatbot that uses large language models (LLMs) to answer user queries by drawing information from the web and providing cited sources within its ...

SINGAPORE: Schools in Beijing will introduce AI courses and teaching methods into the primary and secondary school curriculum starting September, to nurture young talent and boost growth in the ...

AI is changing the world in remarkable ways, from improving health care and education to making life easier for people with disabilities. It’s transforming how people live and work, and its ability to ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

This Holi, Piramal Finance took a creative leap with an AI-generated film, Masti Ke Rang, Neeyat Ke Sang. Crafted entirely by the in-house team, this was a playful experiment to see how AI could ...

“If I were a student today, the first thing I would do is learn AI,” Jensen Huang, CEO of Nvidia, recently declared. What’s good advice for students is probably also good for entrepreneurs.

President Donald Trump said the launch of a low-cost Chinese AI model should be seen as a wake up call for U.S. industries. Trump also announced plans to impose new tariffs on semiconductor imports.

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

NPR's Jon Hamilton has been talking to people who've taken these drugs, and today he has the story of one of the first patients to receive the drug now marketed as Leqembi. JON HAMILTON ...

The FDA has started its review of a subcutaneous injection formulation of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to receive maintenance doses at home, rather than in ...